Skip to main content
Equibles
LIPO logo

LIPO · Lipella Pharmaceuticals Inc. · Metrics

Track LIPO — free

Use LIPO with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research LIPO.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.00 At close · Nov 11
Rebalance outlook locked
Going-concern doubt — flagged Nov 14, 2025

Substantial doubt about the company's ability to continue as a going concern.

“These factors individually and collectively raise substantial doubt about the Company's ability to continue as a going concern. The accompanying unaudited condensed financial statements do not include any adjustments that may result from this uncertainty.”
View the 10-Q filed Nov 14, 2025
Market Cap
$2,773
Shares
4.62M
Volume · Nov 11 43.34K Avg daily vol (3M) 3997

LIPO metrics

58 of 125 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$0.00
Market cap
$2,773

Price action

23 metrics
Price change (1W)
+20.0%
Price change (30D)
+20.0%
Price change (3M)
+200.0%
Price change (6M)
-98.5%
Price change (YTD)
-99.7%
Price change (1Y)
-99.9%
Trailing year
Price change (5Y)
—
52-week high
$0.54
52-week low
$0.00
Change from 52-week high
-99.9%
Change from 52-week low
+200.0%
Annualized volatility
525.7%
Annualized volatility (3M)
—
Implied volatility (30D)
—
IV rank (1Y)
—
IV percentile (1Y)
—
Beta
-1.7
RSI (14D)
36.1
Price vs SMA 50
-98.3%
Price vs SMA 200
-99.7%
Avg volume (3M)
3,997
Relative volume
10.8
Average dollar volume
$2

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
4.62M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
0.0×
reciprocal yield 16,870.7%
P / book
0.0
reciprocal yield 64,386.4%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-230,683.7%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
—

Profitability

9 metrics
Gross margin
—
Operating margin
-1,387.9%
Trailing 12 months
Net margin
-1,367.4%
Gross profit (TTM)
—
Operating profit (TTM)
−$5.41M
Net income (TTM)
−$5.33M
Trailing 12 months
Diluted EPS (TTM)
$-2.43
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
$0.23
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
$-2.44
EBITDA per diluted share (TTM)
$-2.44
Net income per diluted share (TTM)
$-2.41
Operating cash flow per diluted share (TTM)
$-2.05
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
$1.70
Stock compensation per diluted share (TTM)
—
Book value per share
$1.59

Growth

11 metrics
Revenue growth YoY
-100.0%
Year over year
Net income growth YoY
—
Revenue (TTM)
$389,783
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+306.5%
Year over year · more shares
Revenue CAGR (3Y)
+27.4%
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-358.3%
Return on assets
-226.8%
Debt / equity
—
Current ratio
3.2
EBITDA (TTM)
−$5.41M
Free cash flow (TTM)
—
Quick ratio
3.2
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$1.86M
Latest balance sheet
Cash & equivalents
$1.86M
Total assets
$2.35M
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$4.78M
Capital expenditures (TTM)
—
R&D (TTM)
$3.57M
SG&A (TTM)
—
Stock compensation (TTM)
—
R&D / revenue
915.5%
Stock compensation / revenue
—

Ownership (13F)

9 metrics
13F filers
—
13F filer change QoQ
—
Institutional ownership
—
Conviction holders (share of 13F filers)
—
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
—
Holder tenure
—
Price vs estimated holder cost
—

Ownership (registered funds)

1 metrics
Index-fund ownership
0.0%

Short interest

3 metrics
Short interest
0.0%
Latest settlement · 1.9 days to cover
Days to cover
1.9d
Short-squeeze score
37 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1347242 CUSIP 53630L209 13F (30d) 2 filings 1 filers Visit website Investor relations